Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb 14;9(3):167-77.
doi: 10.1038/nrclinonc.2012.2.

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

James P B O'Connor  1 , Alan Jackson, Geoff J M Parker, Caleb Roberts, Gordon C Jayson
Affiliations
Review

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

James P B O'Connor et al. Nat Rev Clin Oncol. .

Abstract

About 100 early-phase clinical trials and investigator-led studies of targeted antivascular therapies--both anti-angiogenic and vascular-targeting agents--have reported data derived from T1-weighted dynamic contrast-enhanced (DCE)-MRI. However, the role of DCE-MRI for decision making during the drug-development process remains controversial. Despite well-documented guidelines on image acquisition and analysis, several key questions concerning the role of this technique in early-phase trial design remain unanswered. This Review describes studies of single-agent antivascular therapies, in which DCE-MRI parameters are incorporated as pharmacodynamic biomarkers. We discuss whether these parameters, such as volume transfer constant (K(trans)), are reproducible and reliable biomarkers of both drug efficacy and proof of concept, and whether they assist in dose selection and drug scheduling for subsequent phase II trials. Emerging evidence indicates that multiparametric analysis of DCE-MRI data offers greater insight into the mechanism of drug action than studies measuring a single parameter, such as K(trans). We also provide an overview of current data and appraise the future directions of this technique in oncology trials. Finally, major hurdles in imaging biomarker development, validation and qualification that hinder a wide application of DCE-MRI techniques in clinical trials are addressed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Cancer Res. 2011 Aug 1;17(15):5152-60 - PubMed
    1. J Clin Oncol. 2008 Jun 20;26(18):2992-8 - PubMed
    1. J Clin Oncol. 2009 Sep 1;27(25):4169-76 - PubMed
    1. J Angiogenes Res. 2009 Sep 21;1:5 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 - PubMed

MeSH terms